{
  "url": "https://openlegislation.uk/eu-decision-2005-171/annex-II",
  "json_url": "https://openlegislation.uk/eu-decision-2005-171/annex-II.json",
  "legislation": "eudn/2005/171",
  "legislation_title": "Commission Decision of 23 February 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 293) (Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Portuguese, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2005/171/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2005-171",
  "path": "annex/II",
  "kind": "annex",
  "number": "II",
  "heading": "ESSENTIAL MEDICAL USES",
  "text": "Quota of controlled substances of Group I that may be used in the production of metered-dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:\n3M (UK)\nAventis (UK)\nBespak (UK)\nBoehringer Ingelheim (DE)\nChiesi (IT)\nGlaxo Smith Kline (UK)\nIG Sprühtechnik (DE)\nInyx Pharmaceuticals (UK)\nIVAX (IE)\nJaba Farmaceutica (PT)\nLab. Aldo-Union (ES)\nOtsuka Pharmaceuticals (ES)\nSicor (IT)\nSchering-Plough (BE)\nV.A.R.I. (IT)\nValeas (IT)\nValois (FR)",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2005/171/annex/II",
    "retrieved_at": "2026-11-01T15:17:58.970072+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}